PARP1 and cancer: While the physiological effect of inhibitors may, in fact, depend on the ratio between these two counteracting enzymes in a particular cancer type, the most recent statistical analysis of long-term renal cancer patients’ survival indicates that PARP1 remains “prognostic, high expression is unfavorable in renal cancer”, but, at the same time, PARG appears to be not prognostic in renal cancer, and its increased density correlates with patients’ survival (Supplemental Fig. S1).